Pursuant to regulations 30 and 46(2) (oa) of the Listing Regulations, Zydus Lifesciences has informed that it attached the transcript of the Company’s Q4 FY24 post results earnings call held on May 17, 2024.
The above information is a part of company’s filings submitted to BSE.